OS Therapies Inc belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for OS Therapies Inc. The previous disclosure was published on 9 May 2025.
Since 2024, the database holds no purchases and 5 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -28.8 m USD.
In the same sector, recent insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Analysts rate OS Therapies Inc Strong Buy (bullish), based on 4 analysts. Average price target: US$8.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2023 · cache
25 of 25 declarations
OS Therapies Inc is a company focused on developing innovative therapies for the treatment of diseases. It is listed on the XNAS market.
Purchases our model currently ranks for the recommendations list.
All recommendations